|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...2425262728293031323334...4041» |
- |||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment open: Extension Study of MT-1303 (clinicaltrials.gov) - Aug 26, 2013
P2, N=400, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Not yet recruiting --> Recruiting
- Enrollment change: Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS (clinicaltrials.gov) - Aug 26, 2013
P1, N=6, Completed, Sponsor: Royan Institute
Not yet recruiting --> Recruiting N=10 --> 6
- Trial completion: Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS (clinicaltrials.gov) - Aug 26, 2013
P1, N=6, Completed, Sponsor: Royan Institute
N=10 --> 6 Recruiting --> Completed
- |||| Enrollment open: Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns (clinicaltrials.gov) - Aug 25, 2013
P4, N=240, Recruiting, Sponsor: Allergan
Recruiting --> Completed Not yet recruiting --> Recruiting
- Nerventra (laquinimod) / Active Biotech, Rebif (human IFN-?-1a) / EMD Serono
Trial withdrawal: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability (clinicaltrials.gov) - Aug 25, 2013
P2, N=0, Withdrawn, Sponsor: Teva Pharmaceutical Industries
Not yet recruiting --> Recruiting Suspended --> Withdrawn
- Nerventra (laquinimod) / Active Biotech, Rebif (human IFN-?-1a) / EMD Serono
Enrollment change: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability (clinicaltrials.gov) - Aug 25, 2013
P2, N=0, Withdrawn, Sponsor: Teva Pharmaceutical Industries
Suspended --> Withdrawn N=400 --> 0
- Rebif (human IFN-β-1a) / EMD Serono
Enrollment change: SOLAR: Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (clinicaltrials.gov) - Aug 22, 2013
P2, N=230, Active, not recruiting, Sponsor: Merck KGaA
N=400 --> 0 N=358 --> 230
- ||| dimethyl fumarate / Generic mfg.
Enrollment closed: MANAGE: Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States (clinicaltrials.gov) - Aug 22, 2013
P4, N=230, Active, not recruiting, Sponsor: Biogen Idec
N=358 --> 230 Recruiting --> Active, not recruiting
- Clinical: The Efficacy of Vitamin K2 n Human Osteoporosis, Blood-vessel Calcification and Sclerosis (clinicaltrials.gov) - Aug 21, 2013
P=N/A, N=60, Completed, Sponsor: Changhua Christian Hospital
- ||||| Copaxone 3TW (glatiramer acetate three times a week) / Teva
Enrollment closed: Safety and Tolerability of Glatiramer Acetate (clinicaltrials.gov) - Aug 21, 2013
P3, N=210, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment change, Metastases: Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction (clinicaltrials.gov) - Aug 21, 2013
P=N/A, N=96, Recruiting, Sponsor: University of Zurich
Recruiting --> Active, not recruiting N=77 --> 96
- Trial termination: Effectiveness of Ankle Foot Orthoses on Gait in Multiple Sclerosis (clinicaltrials.gov) - Aug 20, 2013
P=N/A, N=10, Terminated, Sponsor: University of Texas Southwestern Medical Center
N=77 --> 96 Recruiting --> Terminated; Modifications were made to protocol, new IRB pending
- Enrollment change: Effectiveness of Ankle Foot Orthoses on Gait in Multiple Sclerosis (clinicaltrials.gov) - Aug 20, 2013
P=N/A, N=10, Terminated, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Terminated; Modifications were made to protocol, new IRB pending N=15 --> 10
- | Trial completion: Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis (clinicaltrials.gov) - Aug 19, 2013
P=N/A, N=21, Completed, Sponsor: Brown, Theodore R., M.D., MPH
N=15 --> 10 Recruiting --> Completed
- | dalfampridine / Generic mfg.
Trial completion: A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis (clinicaltrials.gov) - Aug 19, 2013
P4, N=43, Completed, Sponsor: Brown, Theodore R., M.D., MPH
Recruiting --> Completed Recruiting --> Completed
- Enrollment open, Adherence: Development of a Motivational Intervention to Improve Treatment Adherence in MS (clinicaltrials.gov) - Aug 18, 2013
P=N/A, N=80, Recruiting, Sponsor: University of Missouri, Kansas City
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Enrollment closed: A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis (clinicaltrials.gov) - Aug 18, 2013
P3, N=87, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | ATX-MS-1467 / Worg Pharma
Trial completion: ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Aug 16, 2013
P1, N=42, Completed, Sponsor: Apitope Technology (Bristol) Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial initiation date: Gilenya in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Aug 15, 2013
P2a, N=30, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Initiation date: May 2013 --> Aug 2013
- Enrollment open: Gilenya in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Aug 15, 2013
P2a, N=30, Recruiting, Sponsor: Massachusetts General Hospital
Initiation date: May 2013 --> Aug 2013 Not yet recruiting --> Recruiting
- Trial completion: Effects of Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Aug 13, 2013
P=N/A, N=70, Completed, Sponsor: National Taiwan University Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Enrollment change: Fingolimod -Response According to Coping - Evaluation (clinicaltrials.gov) - Aug 8, 2013
P4, N=189, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=250 --> 189
- |||| Trial completion: Fingolimod -Response According to Coping - Evaluation (clinicaltrials.gov) - Aug 8, 2013
P4, N=189, Completed, Sponsor: Novartis Pharmaceuticals
N=250 --> 189 Recruiting --> Completed
- |||||| dalfampridine / Generic mfg.
Enrollment open: A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (clinicaltrials.gov) - Aug 7, 2013
P3, N=128, Recruiting, Sponsor: Biogen Idec
Recruiting --> Completed Not yet recruiting --> Recruiting
- || New P3 trial: A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis (clinicaltrials.gov) - Aug 6, 2013
P3, N=600, Recruiting, Sponsor: Department of Veterans Affairs
- armodafinil / Generic mfg.
Trial completion: Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 5, 2013
P2/3, N=33, Completed, Sponsor: University of Missouri, Kansas City
Not yet recruiting --> Recruiting Enrolling by invitation --> Completed
- |||||||||| dalfampridine / Generic mfg.
New P3 trial: A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (clinicaltrials.gov) - Aug 4, 2013
P3, N=128, Recruiting, Sponsor: Biogen Idec
- | Enrollment open: A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis (clinicaltrials.gov) - Aug 4, 2013
P3, N=600, Recruiting, Sponsor: Department of Veterans Affairs
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- ||||| Radicava (edaravone) / Mitsubishi Tanabe
Enrollment closed: Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Aug 3, 2013
P3, N=128, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- dactolisib (RTB101) / Adicet Bio
Trial withdrawal, Monotherapy, Metastases: A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa (clinicaltrials.gov) - Jul 31, 2013
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- dactolisib (RTB101) / Adicet Bio
Enrollment change, Monotherapy, Metastases: A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa (clinicaltrials.gov) - Jul 31, 2013
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Recruiting --> Withdrawn N=33 --> 0
- | New P2 trial: Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS (clinicaltrials.gov) - Jul 28, 2013
P2, N=12, Recruiting, Sponsor: University of Manitoba
- | minocycline / Generic mfg.
Enrollment change: MinoCIS: Minocycline in Clinically Isolated Syndromes (CIS) (clinicaltrials.gov) - Jul 28, 2013
P3, N=154, Active, not recruiting, Sponsor: Dr. Luanne Metz
N=33 --> 0 N=200 --> 154
- | minocycline / Generic mfg.
Enrollment closed: MinoCIS: Minocycline in Clinically Isolated Syndromes (CIS) (clinicaltrials.gov) - Jul 28, 2013
P3, N=154, Active, not recruiting, Sponsor: Dr. Luanne Metz
N=200 --> 154 Recruiting --> Active, not recruiting
- ||| Extavia (IFN-β-1b) / Novartis
Enrollment change: EPOC: Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (clinicaltrials.gov) - Jul 24, 2013
P4, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=264 --> 200
- |||| Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: SELECTION: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jul 24, 2013
P2, N=517, Completed, Sponsor: Biogen Idec
N=264 --> 200 Active, not recruiting --> Completed
- | H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
New P2 trial: A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Jul 22, 2013
P2, N=40, Active, not recruiting, Sponsor: Questcor Pharmaceuticals, Inc.
- |||||||||| Circadin (melatonin prolonged release) / Lundbeck, Neurim, Flynn Pharma, Grupo Insud, Biocodex, Kuhnil Pharma
New P3 trial: Efficacy and Safety of Circadin (clinicaltrials.gov) - Jul 22, 2013
P3, N=120, Recruiting, Sponsor: Neurim Pharmaceuticals Ltd.
- ||| glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Patient reported outcomes: Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=332, Recruiting, Sponsor: Biogen Idec
- | Circadin (melatonin prolonged release) / Lundbeck, Neurim, Flynn Pharma, Grupo Insud, Biocodex, Kuhnil Pharma
New P1 trial: Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances (clinicaltrials.gov) - Jul 17, 2013
P1, N=16, Completed, Sponsor: Neurim Pharmaceuticals Ltd.
- ||| Rebif (human IFN-?-1a) / EMD Serono
Enrollment open, Adherence: EMR 200136-567: Adherence Trial With MS LifeLines (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=306, Recruiting, Sponsor: EMD Serono
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Exercise in Severely Disabled Patients With MS (clinicaltrials.gov) - Jul 16, 2013
P1, N=12, Completed, Sponsor: University of Aarhus
Not yet recruiting --> Recruiting Recruiting --> Completed
- | everolimus / Generic mfg.
Enrollment change: RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM (clinicaltrials.gov) - Jul 14, 2013
P1/2, N=36, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Completed N=30 --> 36
- | everolimus / Generic mfg.
Trial completion: RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM (clinicaltrials.gov) - Jul 14, 2013
P1/2, N=36, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
N=30 --> 36 Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Enrollment open: INSPIREt: Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jul 11, 2013
P2, N=24, Recruiting, Sponsor: Queen Mary University of London
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed: ASCEND: A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jul 11, 2013
P3, N=856, Active, not recruiting, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- olesoxime (TRO19622) / Roche
Enrollment closed: Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. (clinicaltrials.gov) - Jul 10, 2013
P1, N=44, Active, not recruiting, Sponsor: Trophos
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- ||| Trial completion: Digital Ulceration (clinicaltrials.gov) - Jul 10, 2013
P=N/A, N=630, Completed, Sponsor: Actelion
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- methylphenidate tablet / Generic mfg.
New P2/3 trial: Methylphenidate to Improve Balance and Walking in MS (clinicaltrials.gov) - Jul 9, 2013
P2/3, N=24, Recruiting, Sponsor: Oregon Health and Science University
- |||| teriflunomide / Generic mfg.
Enrollment open, Patient reported outcomes: TERI-PRO: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (clinicaltrials.gov) - Jul 9, 2013
P4, N=1000, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Not yet recruiting --> Recruiting